Immunological Characterization of Blood of Normal Individuals
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Immunological Characterization of Blood of Normal Individuals|
- Blood content differences between the lung disease and healthy control populations [ Time Frame: Day 1 ] [ Designated as safety issue: No ]Test for differences in the blood of individuals with lung disease and normal healthy controls.
- Genetic expression of relevant genes between the lung disease and healthy control populations [ Time Frame: Day 1 ] [ Designated as safety issue: No ]Test for genetic differences in the blood of individuals with lung disease and normal healthy controls.
- Saliva and urine analysis results compared to blood content results between the lung disease and healthy control populations. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]Analyze saliva and urine along with the blood sample in order to compare the information in the blood with the saliva and urine.
- Identify diagnostic and prognostic indicators for lung disease [ Time Frame: December 2020 ] [ Designated as safety issue: No ]Develop and test possible diagnostic and prognostic indicators for various lung diseases.
- Develop possible treatment for lung disease [ Time Frame: December 2020 ] [ Designated as safety issue: No ]Develop and test possible reprogramming of blood cells to promote vessel formation as a way to prevent tumor metastases and modify the progression of specific lung diseases.
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2011|
|Estimated Study Completion Date:||December 2020|
|Estimated Primary Completion Date:||December 2020 (Final data collection date for primary outcome measure)|
Healthy Volunteer without lung disease
Other: No intervention
There is no intervention for this study
Blood will be obtained via peripheral venipuncture. The blood will be divided into components (e.g. plasma, serum, microvesicles, and cells) then analyzed. Flow cytometry will be used to determine cell and microvesicle subsets. RNA will be extracted from the various components of blood and will be subjected to gene and microRNA profiling to determine gene expression. DNA will be isolated from the cells to be used in studies investigating epigenetic regulation of genes identified in the screens. Protein will also be isolated from the multiple components to examine the impact of genetic regulation by epigenetic mechanisms or microRNA on protein expression. Peripheral blood mononuclear cells will be placed in tissue culture for study.
Saliva and urine will be obtained the same day as blood for testing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01386892
|United States, Ohio|
|The Ohio State University|
|Columbus, Ohio, United States, 43210|
|Principal Investigator:||Clay Marsh, M.D.||Ohio State University|